National Webinar - Forecast of Drug Costs in the Private Drug Plan Market, 2013-2017

February 27, 2014 1:00 PM to 2:00 PMBroadcasted Webinar, Eastern Time Zone (EST)
Area of Interest: Benefits Format: Web
*This webinar is free of charge for CPBI Members. The non-member fee is $65 + taxes.
Fees and Registration
Membership TypesRegular Price
Regular membership$0.00 CDN
Associate$0.00 CDN
Student$0.00 CDN
Non Member$65.00 CDN
Event: ‘Event Full’
Cancellation Policy
Continuing Education Requirements for CPBI National Webinars: CE credits will be offered through partnerships with provincial insurance councils across Canada, The Institute for Advanced Financial Education (Advocis) and La Chambre de sécurité financière. Participants are required to Login to the live session by entering their Full Name as per CPBI profile;
Participants must be present for the duration of the session; Participants will be asked to remain online following the presentation to complete a short test comprised of 3 to 4 questions as a proof of attendance. The test will be offered during the live session; participants who do not attend the live session will not be permitted to take the test or qualify to receive CE credits.

Canadian employers are faced with cost pressures and other challenges such as an aging workforce and a rapidly changing economy and business environment. Concerns have been expressed that specialty and biologic drugs make up a growing proportion of their overall drug plan costs and that private drug plan expenditures on new medicines may threaten the sustainability of private sector drug plans. As well, some employees are becoming increasingly concerned about their drug coverage to treat chronic conditions and about having access to the appropriate treatment.

To inform the public about future drug costs, Rx&D commissioned IMS Brogan, a global leader in healthcare market data and measurement, to conduct a five year forecast of drug costs for private drug plans from 2013-2017.

Join us for this live webinar where Brett Skinner, Executive Director of Health and Economic Policy at Rx&D, presents the methodology and findings of the forecast and explains the implications for the sustainability of the private drug plan system in Canada. You will learn:

  • The forecasted market growth for prescription drug costs;
  • The driving factors and assumptions utilized;
  • How to interpret the findings from the forecast.



Brett J Skinner, Ph.D.
Executive Director, Health and Economic Policy, Rx&D

Dr. Brett J Skinner is Executive Director of Health and Economic Policy at Rx&D. He is also the Founder and CEO of the non-profit think-tank Canadian Health Policy Institute (CHPI). Brett has a Ph.D. from the University of Western Ontario, where he has lectured in both the Faculty of Health Sciences and the Department of Political Science.